Therapeutic approaches for women predisposed to breast cancer

Annual Review of Medicine

Volumn 62, Issue , 2011, Pages 295-306

  Nathanson, Katherine L ^a   Domchek, Susan M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BRCA1; BRCA2; breast MRI; PARP inhibitors; salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST SELF EXAMINATION; CANCER MORTALITY; CANCER PREVENTION; CANCER RELAPSE; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; HETEROZYGOTE; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MASTECTOMY; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; RISK REDUCTION; SALPINGOOOPHORECTOMY; SYSTEMIC THERAPY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASTECTOMY; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; POLY(ADP-RIBOSE) POLYMERASES; RISK; TAMOXIFEN; TREATMENT OUTCOME;

EID: 79551598937     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-med-010910-110221     Document Type: Article

References (82)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
2. Wooster R, Neuhausen SL, Mangion J, et al. 1994. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265:2088-90
3. ?) 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31:55-59
4. Seal S, Thompson D, Renwick A, et al. 2006. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 38:1239-41
5. Rahman N, Seal S, Thompson D, et al. 2007. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39:165-67
6. Meindl A, Hellebrand H, Wiek C, et al. 2010. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet. 42:410-14
7. Easton DF, Pooley KA, Dunning AM, et al. 2007. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087-93
8. Thomas G, Jacobs KB, Kraft P, et al. 2009. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat. Genet. 41:579-84
9. Turnbull C, Ahmed S, Morrison J, et al. 2010. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat. Genet. 42:504-7
10. Ford D, Easton DF, Stratton M, et al. 1998. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62:676-89
11. Struewing JP, Hartge P, Wacholder S, et al. 1997. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336:1401-8
12. Chen S, Parmigiani G. 2007. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 25:1329-33
13. Antoniou A, Pharoah PD, Narod S, et al. 2003. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72:1117-30
14. Daly MB, Axilbund JE, Buys S, et al. 2010. Genetic/familial high-risk assessment: breast and ovarian. J. Natl. Compr. Canc. Netw. 8:562-94
15. Saslow D, Boetes C, Burke W, et al. 2007. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J. Clin. 57:75-89
16. Claus EB, Risch N, Thompson WD. 1994. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prevention. Cancer 73:643-51
17. Kriege M, Brekelmans CT, Boetes C, et al. 2004. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N. Engl. J. Med. 351:427-37
18. Warner E, Plewes DB, Hill KA, et al. 2004. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-25
19. Leach MO, Boggis CR, Dixon AK, et al. 2005. Screening with magnetic resonance imaging and mam-mography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365:1769-78
20. Kuhl CK, Schrading S, Leutner CC, et al. 2005. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J. Clin. Oncol. 23:8469-76
21. Lehman CD, Blume JD, Weatherall P, et al. 2005. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 103:1898-905
22. Sardanelli F, Podo F, D'Agnolo G, et al. 2007. Multicenter comparative multimodality surveillance of womenatgenetic-familial high risk for breast cancer (HIBCRIT study): interim results.Radiology 242:698-715
23. Kuhl C, Weigel S, Schrading S, et al. 2010. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J. Clin. Oncol. 28:1450-57
24. Warner E, Messersmith H, Causer P, et al. 2008. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann. Intern. Med. 148:671-79
25. Lehman CD, Isaacs C, Schnall MD, et al. 2007. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 244:381-88
26. Hartmann LC, Sellers TA, Schaid DJ, et al. 2001. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl. Cancer Inst. 93:1633-37
27. Hartmann LC, Schaid DJ, Woods JE, et al. 1999. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340:77-84
28. Rebbeck TR, Friebel T, Lynch HT, et al. 2004. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol. 22:1055-62
29. Meijers-Heijboer H, van Geel B, van Putten WL, et al. 2001. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 345:159-64
30. Domchek SM, Friebel TM, Singer CF, et al. 2010. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967-75
31. Kurian AW, Sigal BM, Plevritis SK. 2010. Survival analysisof cancer risk reduction strategies for BRCA1/2 mutation carriers. J. Clin. Oncol. 28:222-31
32. van Sprundel TC, Schmidt MK, Rookus MA, et al. 2005. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br. J. Cancer 93:287-92
33. Levine DA, Argenta PA, Yee CJ, et al. 2003. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J. Clin. Oncol. 21:4222-27
34. Rebbeck TR, Kauff ND, Domchek SM. 2009. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomyinBRCA1orBRCA2 mutation carriers. J. Natl. Cancer Inst. 101:80-87
35. Rebbeck TR, Lynch HT, Neuhausen SL, et al. 2002. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346:1616-22
36. Rebbeck TR, Levin AM, Eisen A, et al. 1999. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1. J. Natl. Cancer Inst. 91:1475-79
37. Eisen A, Lubinski J, Klijn J, et al. 2005. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J. Clin. Oncol. 23:7491-96
38. Kauff ND, Domchek SM, Friebel TM, et al. 2008. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J. Clin. Oncol. 26:1331-37
39. Kauff ND, Satagopan JM, Robson ME, et al. 2002. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346:1609-15
40. Finch A, Beiner M, Lubinski J, et al. 2006. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296:185-92
41. Domchek SM, Friebel TM, Neuhausen SL, et al. 2006. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 7:223-29
42. Parker WH, Jacoby V, Shoupe D, Rocca W. 2009. Effect of bilateral oophorectomy on women's long-term health. Women's Health (London) 5:565-76
43. Rivera CM, Grossardt BR, Rhodes DJ, et al. 2009. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 16:15-23
44. Rocca WA, Bower JH, Maraganore DM, et al. 2007. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69:1074-83
45. Rivera CM, Grossardt BR, Rhodes DJ,etal. 2009. Increased mortality for neurological and mental diseases following early bilateral oophorectomy. Neuroepidemiology 33:32-40
46. Rocca WA, Grossardt BR, de Andrade M, et al. 2006. Survival patterns after oophorectomy in pre-menopausal women: a population-based cohort study. Lancet Oncol. 7:821-28
47. Rebbeck TR, Friebel T, Wagner T, et al. 2005. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol. 23:7804-10
48. Eisen A, Lubinski J, Gronwald J, et al. 2008. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J. Natl. Cancer Inst. 100:1361-67
49. Fisher B, Costantino JP, Wickerham DL, et al. 1998. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90:1371-88
50. Gail MH, Costantino JP, Bryant J, et al. 1999. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J. Natl. Cancer Inst. 91:1829-46
51. Fisher B, Costantino JP, Wickerham DL, et al. 2005. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 97:1652-62
52. King MC, Wieand HS, Hale K, et al. 2001. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: a genomic resequencing study in the NSABP-P1 Breast Cancer Prevention Trial. Am. J. Hum. Genet. 69S:272
53. Narod SA, Brunet JS, Ghadirian P, et al. 2000. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876-81
54. Gronwald J, Tung N, Foulkes WD, et al. 2006. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int. J. Cancer 118:2281-84
55. Antoniou AC, Rookus M, Andrieu N, et al. 2009. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol. Biomarkers Prev. 18:601-10
56. Narod SA, Dube MP, Klijn J, et al. 2002. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 94:1773-79
57. Iodice S, Barile M, Rotmensz N, et al. 2010. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur. J. Cancer 46:2275-84
58. Lakhani SR, Jacquemier J, Sloane JP, et al. 1998. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 90:1138-45
59. Lakhani SR, Reis-Filho JS, Fulford L, et al. 2005. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 11:5175-80
60. Kriege M, Seynaeve C, Meijers-Heijboer H, et al. 2009. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 27:3764-71
61. O'Donovan PJ, Livingston DM. 2010. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 31:961-67
62. Price M, Monteiro AN. 2010. Fine tuning chemotherapy to match BRCA1 status. Biochem. Pharmacol. 80:647-53
63. Lafarge S, Sylvain V, Ferrara M, Bignon YJ. 2001. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20:6597-606
64. Mullan PB, Quinn JE, Gilmore PM, et al. 2001. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 20:6123-31
65. Tutt A, Ashworth A. 2008. Can genetic testing guide treatment in breast cancer? Eur. J. Cancer 44:2774-80
66. Byrski T, Gronwald J, Huzarski T, et al. 2008. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res. Treat. 108:289-96
67. Byrski T, Huzarski T, Dent R, et al. 2009. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat. 115:359-63
68. Byrski T, Gronwald J, Huzarski T, et al. 2010. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J. Clin. Oncol. 28:375-79
69. Shanley S, McReynolds K, Ardern-Jones A, et al. 2006. Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin. Cancer Res. 12:7033-38
70. Bordeleau L, Panchal S, Goodwin P. 2010. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res. Treat. 119:13-24
71. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. 2007. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N. Engl. J. Med. 357:115-23
72. Robson ME, Chappuis PO, Satagopan J, et al. 2004. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 6:R8-R17
73. Moller P, Evans DG, Reis MM, et al. 2007. Surveillance for familial breast cancer: differences in outcome according to BRCA mutation status. Int. J. Cancer 121:1017-20
74. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al. 2007. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur. J. Cancer 43:867-76
75. Annunziata CM, O'Shaughnessy J. 2010. Poly(ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin. Cancer Res. 16:4517-26
76. Bryant HE, Schultz N, Thomas HD, et al. 2005. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-17
77. Farmer H, McCabe N, Lord CJ, et al. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-21
78. Fong PC, Boss DS, Yap TA, et al. 2009. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361:123-34
79. Tutt A, Robson M, Garber JE, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-44
80. Audeh MW, Carmichael J, Penson RT, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245-51
81. O'Shaughnessy OC, Pippen J, Yoffe M, et al. 2009. Efficacy of BSI-201, a poly(ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer: results of a randomized trial. J. Clin. Oncol. 27:6s (Abstr.)
82. Evers B, Drost R, Schut E, et al. 2008. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14:3916-25